CliffBio
small molecule

AZACITIDINE

AZACITIDINE

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameAZACITIDINE
Active ingredientAZACITIDINE
Strength100MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2016
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

AZACITIDINE patent cliff — loss of exclusivity — | CliffBio